Optiobiotix strengthens its supply chain
(AIM:OPTI ) has announced a contract manufacturing agreement with Fipros A/S in Denmark.
Fipros (www.fipros.dk) is a Danish contract manufacturer founded in 1992 with operations in Sweden and Denmark. The terms of the agreement grant Fipros the rights to utilise OptiBiotix's IP to manufacture SlimBiome® under licence.
The agreement creates a source of supply within the European Union and has been entered into as part of the Company’s strategy to de-risk the Company’s supply chain in case of a ‘hard Brexit’. Manufacturing within the EU will support the commercial launch of SlimBiome® in Poland and Germany as previously announced.
Shares in Opti traded up 7% following the announcement.
Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division, commented: "We are very pleased to work with Fipros to manufacture SlimBiome® within the European Union. The agreement is key as it helps us lower the cost of trade, support our existing and future European distributors and build contingency in the supply chain which is a key requirement from large commercial partners who do not want to be single-sourced. In addition, Fipros has a Certification and Accreditation Administration of the People's Republic of China (CNCA) registration thus enabling us to fast track future possible exports to China."
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.